Abstract B100: Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell–engineered mesothelin-redirected CAR-engineered invariant natural killer T cells
Pancreatic cancer (PC) remains one of the leading causes of cancer-related mortality worldwide, with most patients diagnosed at advanced stages and more than half presenting with metastatic disease at diagnosis. Although chimeric antigen receptor (CAR)-T cell therapy has shown promise for the treatment of PC, its cli...